Immunotherapy has radically changed how cancer is treated, including skin cancer. Yet in this age of immunotherapy, is there still a place for hedgehog inhibitors in the treatment tool box?
In this Next Steps in Derm video interview, Vishal A. Patel, MD, FACMS, ODAC’s guest advisor for surgical dermatology, shares the important role that hedgehog inhibitors should still play in cutaneous oncology. Watch as Dr. Patel outlines the two approved medications and how they work. Plus learn what you need to know to choose the best treatment for your patients.
Want more updates in the treatment of skin cancer? Register for ODAC 2026 and attend the following sessions:
- Hedgehog Inhibitors for Basal Cell Carcinoma: Optimizing Use and Overcoming Challenges – Expert Panel
- Beyond the Blade: Surveillance, GEP, and Radiation Insights for High-Risk Skin Cancers
- Cutaneous Oncology Updates: New Approaches to Melanoma and Nonmelanoma Skin Cancers
The skin cancer slate at ODAC 2026 features practical updates from experts in the field, including Dr. Patel, who is the recipient of the 2025 Elaine H. Snyder Cancer Researcher Award, as well as C. William Hanke, MD, FAAD, and David Miller, MD, PhD, FAAD.
